Siu L - Search Results

1

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. Eckhardt SG, et al. Among authors: siu l. J Clin Oncol. 2000 Dec 15;18(24):4086-97. doi: 10.1200/JCO.2000.18.24.4086. J Clin Oncol. 2000. PMID: 11118470

2

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.

Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ. Siu LL, et al. J Clin Oncol. 1998 Mar;16(3):1122-30. doi: 10.1200/JCO.1998.16.3.1122. J Clin Oncol. 1998. PMID: 9508199 Clinical Trial.

3

A risk-benefit assessment of irinotecan in solid tumours.

Siu LL, Rowinsky EK. Siu LL, et al. Drug Saf. 1998 Jun;18(6):395-417. doi: 10.2165/00002018-199818060-00002. Drug Saf. 1998. PMID: 9638386

4

Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx.

Siu LL, Czaykowski PM, Tannock IF. Siu LL, et al. J Clin Oncol. 1998 Jul;16(7):2514-21. doi: 10.1200/JCO.1998.16.7.2514. J Clin Oncol. 1998. PMID: 9667272 Clinical Trial.

5

Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.

Siu LL, Attardo G, Izbicka E, Lawrence R, Cerna C, Gomez L, Davidson K, Finkle C, Marsolais C, Rowinsky EK, Von Hoff DD. Siu LL, et al. Ann Oncol. 1998 Aug;9(8):885-91. doi: 10.1023/a:1008387019062. Ann Oncol. 1998. PMID: 9789612 Free article.

6

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.

Siu LL, Von Hoff DD, Rephaeli A, Izbicka E, Cerna C, Gomez L, Rowinsky EK, Eckhardt SG. Siu LL, et al. Invest New Drugs. 1998;16(2):113-9. doi: 10.1023/a:1006049227744. Invest New Drugs. 1998. PMID: 9848574

7

New anticancer agents.

Britten C, Hammond L, Hidalgo M, Rothenberg ML, Sharma A, Sharma S, Siu L, Villalona-Calero M, Weiss GR. Britten C, et al. Among authors: siu l. Cancer Chemother Biol Response Modif. 1999;18:178-209. Cancer Chemother Biol Response Modif. 1999. PMID: 10800483 Review. No abstract available.

8

Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.

Britten CD, Baker SD, Denis LJ, Johnson T, Drengler R, Siu LL, Duchin K, Kuhn J, Rowinsky EK. Britten CD, et al. Among authors: siu ll. Clin Cancer Res. 2000 Sep;6(9):3459-68. Clin Cancer Res. 2000. PMID: 10999729

9

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.

Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM. Patnaik A, et al. Among authors: siu ll. J Clin Oncol. 2000 Nov 1;18(21):3677-89. doi: 10.1200/JCO.2000.18.21.3677. J Clin Oncol. 2000. PMID: 11054441 Clinical Trial.

10

Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.

Patnaik A, Rowinsky EK, Tammara BK, Hidalgo M, Drengler RL, Garner AM, Siu LL, Hammond LA, Felton SA, Mallikaarjun S, Von Hoff DD, Eckhardt SG. Patnaik A, et al. Among authors: siu ll. J Clin Oncol. 2000 Dec 1;18(23):3974-85. doi: 10.1200/JCO.2000.18.23.3974. J Clin Oncol. 2000. PMID: 11099327 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

683 results

Search Page

Filters